Diamyd Medical receives increased patent protection
Diamyd Medical today announced that the U.S. Patent Attorney at the University of California, Los Angeles, (UCLA), has informed that another Diamyd Medical licensed UCLA patent application will be granted. The patent includes protection for treating type 1 diabetes with the combination GABA and the diabetes vaccine Diamyd® and has a maturity until September 27, 2031. Previously, a patent within the same patent family has been granted covering diabetes treatment with GABA and preproinsulin or an immunogenic fragment thereof.
Diamyd Medical has previously licensed several approved independent patents covering treatment with the Company's candidate drugs GAD65 (the diabetes vaccine Diamyd®) and GABA for metabolic syndrome, type 1 diabetes, type 2 diabetes, rheumatoid arthritis and inflammatory diseases
“We continue to strengthen our patent portfolio with new applications," says Ulf Hannelius, CEO of Diamyd Medical. “Promising preliminary results with intralymphatic administration of Diamyd® in newly diagnosed type 1 diabetes patients mean that we now, with a new follow-up pivotal Phase II study, take this patent pending application closer to market. Combination treatment with GABA and Diamyd® can lead to a follow-up application that not only extinguishes autoimmune inflammation, thus preserving the patient's own insulin production, but also contributes to the regrowth of insulin-producing beta cells. This can in turn lead to a complete cure.”
A clinical trial is currently ongoing in the U.S. at the University of Alabama at Birmingham, where the effect of GABA and the combination GABA and Diamyd® is evaluated in 95 newly diagnosed type 1 diabetes patients. A follow-up Phase II study in 80 newly diagnosed type 1 diabetes patients where Diamyd® is given directly into the lymph node is expected to start recruiting patients this fall.
About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.
Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Five clinical studies are ongoing with Diamyd®. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB. Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.
Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.
For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.
This information is information that Diamyd Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. This is an English translation of information that was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on May 15, 2017.
Tags: